|PR Center |Trace
With the management philosophy, “with respect towards human beings, let us do our best for health and welfare of humankind,” Il-Yang Pharm.Co.,Ltd has been striving to produce good medicine for the last half-century. After taking the first step in 1946 when the country had no established pharmaceutical industry, the company has been growing as a global pharmaceutical firm based on state-of-art facilities in Yongin and Eumseong vaccine factories. Also, Il-Yang is exporting various medicinal products to over 30 countries around the world including the US and Europe, and began operating the Chinese local factory, Yangju Il-Yang Pharm. Co., Ltd., opening up a new era of producing locally-finished pharmaceutical products. As a company with a sense of responsibility for human life, Il-Yang Pharm will continue to develop cutting-edge medicine through relentless research and effort for welfare of people.
1946. 07. Acquired Hanseong Pharmaceutical Company(漢城藥館),
and established Gongsin Pharmaceutical Company(共信藥業社)
after obtaining the approval from Hanji Medicine Corporation(限地藥鍾商)
1957. 05. Obtained the license for pharmaceutical business,
and established Seonrim Pharmaceutical Company 1957. 07. Launched the digestive drug <Norumo tab>, the first product of the company
1961. 06. Renamed to Ilyang Pharmaceutical Industry Corporation
1971. 07. Launched <Wonbi-D>, the ginseng nutritious tonic
1971. 12. Renamed to Ilyang Pharmaceutical Industry Co.,Ltd, and incorporated
1972. 04. Selected as excellent pharmaceutical company on the Day of Health,
and awarded the commendation from the Minister of Health and Welfare 1974. 08. Listed on Korea Stock Exchange
1981. 12. Exceeded $1 million in drug exports(total: $1,200,263)
1990. 04. Launched <Young bi-cheon>
1991. 05. Started the operation of State-of-the-art 1000BPM handmade production line at G.M.P factory in Yongin
1991. 05. Renamed to Ilyang Pharmaceutical Co., Ltd
1995. 11. Awarded the Industrial Service Merit for reaching the milestone of 100 million <Wonbi> bottles, and won the $10 million export tower prize
1996. 03. Won the Gold Tower Industrial Medal on the 23rd Day of Commerce & Industry
1996. 09. Obtained the U.S. substance patent for the next-generation gastric ulcer treatment drug
1996. 10. Established TongHua IL-YANG (China)
1997. 02. Obtained the U.S. and Japan substance patent for the liver disease treatment drug G009
1998. 04. Obtained the U.S. patent for IY-81149, the next-generation anti-ulcer treatment drug
1998. 07. Established YangZhou IL-YANG (China)
2000. 09. The authentic gGinseng drink
2001. 02. Entered into a contract with Baxter, the multinational company, for the exclusive sale of the essential drugs
for patients in intensive care unit and emergency room
2001. 05. Exceeded KRW 10 billion in sales of "Hytrin", the prostatic hypertrophy treatment drug approved by KFDA,
carving out the largest share in the market
2001. 12. Completed the construction of the nation’s only state-of-the-art BGMP inorganic synthesis factory with an
annual production capacity of 2000 tons
2001. 12. Entered into the license agreement with China's Livzon for "IY81149"
2002. 05. Obtained the U.S. patent for fine enteric coated granules
2002. 12. Acquired the domestic exclusive sales and goodwill for “Uprima Tab” the erectile dysfunction treatment drug
2003. 09. Awarded the Stone Order of Industrial Service Merit on the 9th Day of statistics
2004. 02. BIO revolution - Simultaneous clinical progression for ILPRAZOLE in five countries worldwide
2004. 03. Exclusive domestic sale of RESPeRATE, the world’s only hypertension treatment instrument approved by the
2004. 05. Entered into an exclusive license agreement with the U.S.-based Alliance for the OXIGENT, the artificial blood
(it has excellent oxygen-carrying capacity and therefore can substitute the red blood cell transfusion)
2005. 01. Released the Tong-sim-rak(通心絡), the new-concept herbal medicine for heart disease/angina/
2005. 02. Obtained the German patent for the anti-ulcer injection formulation(phase 3 clinical trial is scheduled in
4 countries including Singapore)
2005. 04. Embarked on phase 3 clinical trial for “Ilaprazole”, the next-generation new material anti-ulcer agent
(After the experiment following the multinational phase 2 clinical trial, an agreement was entered into with
GCRC to conduct the global phase 3 clinical trial worldwide, including Korea)
2005. 06. Developed the new leukemia treatment drug "IY-5511"
2005. 10. Developed raw material from Phellinus linteus mycelia for anti-malignant tumor agents
2005. 11. Successfully synthesized the Tamiflu, the bird flu treatment drug
2006. 02. Completed the phase 3 clinical trial in China for "Ilaprazole", the next generation anti-ulcer agent
2006. 04. Submitted the application to China’s FDA for the approval of the sale of new drug, "Ilaprazole",
the next generation anti-ulcer agent
2007. 03. Successfully completed the animal experiment of Leukemia treatment drug "IY-5511”
2007. 08. Completed the phase 2 clinical trial in the United States for Ilaprazole
2007. 10. Completed the application for the approval of new drug, “Ilaprazole”
2008. 04. Obtained the approval of Ilaprazole based on KFDA standards and the test method & finished manufactured
2008. 05. Obtained the DMF approval of Ilaprazole from KFDA
2008. 06. Obtained the KFDA approval of the phase 1 and 2 clinical trial(IND) for the next-generation leukemia
treatment drug IY5511
2008. 07.29. Clinical trial of the next-generation leukemia treatment drug IY5511, conducted by Catholic University
School of Medicine
2008. 08. Published the statistics analytical results of phase 3 clinical trial for Ilaprazole in six countries
of Southeast Asia
2008. 09. Passed the KFDA’s safety effectiveness review of Ilaprazole, the next-generation anti-ulcer agent
2008. 10. Obtained the new drug approval for Ilaprazole "Noltec", which is the next-generation anti-ulcer agent and the
nation’s 14th new indigenous drug
2008. 11. Research grant of KRW 3.8 billion, the largest for any single research project, for IY5511, the next-generation
leukemia treatment drug
2008. 12. Established the SIS Immunology Research Center jointly in collaboration among Samsung Seoul Hospital,
Ilyang Pharmaceutical, and Sookmyung Women's University
2009. 03. Award the Grand Prize for "Noltec”, the next-generation anti-ulcer agent, in the category of new drug
2009. 03. Obtained the U.S. patent for IY5511, the leukemia treatment drug
2009. 05. Kim Dong-yeon took the office of President
2009. 05. Extended the patent term of Ilaprazole, the next-generation anti-ulcer agent, to 2027
2009. 05. Supplied the raw materials of Ilaprazole, the next-generation anti-ulcer agent, exclusively to India-based Merck
2009. 06. Exported the finished pharmaceutical product to Indonesia, etc., under the name of Ilaprazole,
the next-generation anti-ulcer agent
2009. 07. Succeeded in phase 1 clinical trial of “IY5511”, the leukemia treatment drug, and embarked on the
global phase 2 clinical trial
2009. 12. Started the sale of "Noltec", the 14th new indigenous drug
2009. 12. Won the medal of excellence in 2009 National Research & Development Excellence"
2010. 01. Acquired the healthy technology[HT] certification mark for Noltec
2010. 04. Discovered the Cytokine, the body defense system control & stimulus signal substance, for the first time
2010. 04. Obtained the approval of the phase 2 clinical trial(IND) in India and Thailand for IY5511, the next-generation
leukemia treatment drug
2010. 04. 2010. 04. Invented the new Peptide, the angiogenesis-promoting substances
2010. 05. Groundbreaking ceremony of vaccine manufacturing plant in Eumseong, Chungbuk
2010. 11.18. Ilyang Pharmaceutical developed the antiviral substances of new mechanism
2010. 12.15. Ilyang Pharmaceutical was designated to undertake the pilot project for new drug development
and launched the 4 types of cytokines for research purpose
2011. 02. Completed the registration of phase 3 clinical trial for anti-ulcer agent "Noltec” reflux esophagitis
2011. 04. Held the ceremony to mark the completion of the vaccine manufacturing plant in Eumseong, Chungbuk
2011. 05. Obtained the approval of phase 3 clinical trial for "radotinib", the super leukemia treatment drug
2011. 07. Submitted the application for new drug status of "radotinib", the super leukemia treatment drug
2011. 07. Radotinib" was confirmed under the "WHO International Nonproprietary Name(INN)”
2011. 07. Obtained the U.S. patent for anti-ulcer agent "Ilaprazole"
2011. 08. Started the phase 3 clinical trial for "radotinib"
2011. 09. Obtained the substance patent of Canada and New Zealand for "radotinib"
2012. 01. Obtained the final approval of "KFDA for Supect(ingredient name: radotinib), the super leukemia treatment drug
2012. 02. Ilyang Pharmaceutical developed “Supect”, Asia's first super leukemia treatment drug, won the Grand Prize in
the 13th Korea Republic New Drug Development Award in the category of new drug development
2012. 03. SIS Immunology Research Center - Obtained the utilization patent for the invention of components that
enhances the hair growth function using the fat stem cells
2012. 06. Ilyang Pharmaceutical won the "New Drug Grand Prize" in Osong New Drug Award
2012. 07. Ilyang Pharmaceutical, the mechanism of action completely different from the previous one
Presented the super antiviral substance to the 2012 World Society for Virology for the first time,
2012. 09. Noltec, the anti-ulcer drug, completed the addition of the indication for reflux esophagitis
2012. 10. Entered into a contract with Dae-woong Pharmaceuticals for the domestic sale of “Supect”, Asia's first super
leukemia treatment drug
2012. 10. Ilyang Pharmaceutical was awarded the commendation from the President on the 26th Day of Medicine
2013. 01. Presented the results of phase II clinical trial of “Supect”, Asia's first super leukemia treatment drug,
to the International Society of Hematology
2013. 02. Kim Dong-Yeon, the President, took office as Chairman of New Drug Association
2013. 03. Selection of antiviral substance IY7640 as study assignment of the government-affiliated “business unit of
governmental department” against novel influenza
2013. 04. ‘Supect’, the best estimation as study assignment supported by the Ministry of Health and Welfare
2013. 06. Conclusion of a term sheet of ‘Noltec’, ‘Supect’ with Abdi Ibrahim Pharmaceuticals in Turkey
2013. 06. Conclusion of MOU of production and sales of ‘Supect’ with Yangzhou Ilyang in China
2013. 08. Permission approval of a flu vaccine of Ilyang Pharmaceuticals from KFDA
2013. 08. Yongin factory, acquisition of the approval qualification as a foreign manufacturer for quasi-medicines
from Japanese Ministry of Health, Labor and Welfare
2013. 08. Consecutive registration of ‘Noltec’ as an antiulcer drug in international papers
2013. 08. ‘Supect’ as a super leukemia medicine, selection in 100 items among excellent results from the national study
2013. 09. Conclusion of the exclusive sales and license contract of ‘Noltec’ as the antiulcer drug with Life Pharma
Pharmaceuticals in UAE
2013. 10. Conclusion of a main contract of license of ‘Supect’ with Yangzhou Ilyang in China
2013. 12. Representative Kim Dong-Yeon, receiving the president prize as a man of merit of health and medical service
2014. 02. Conclusion of a main contract of “No1tec” with with Abdi Ibrahim Pharmaceuticals in Turkey
2014. 02. Completed the enrollment of patients in phase 3 clinical trial for SUPECT
2014. 02. Government held “Transgovernmental Enterprise for Pandemic Influenza in Korea(TEPIK)” Contest
In the Final Selection, a New Influenza Vaccine, H7N9 form, Selected as Research Project
2014. 03 Entered into the license agreement for ‘SUPECT’ with ABDI IBRAHIM pharmaceuticals, the number one
pharmaceutical company in Turkey.
2014. 05 Respiratory Syncytial Virus(RSV) Treatment Substance Developed
2014. 05 MSA Signed with Quintiles, the Leading Global CRO
2014. 05 Term Sheet Signed with R-pharm, Russian Pharmaceutical Company
2014. 05 Registered Noltec Manufacturing Site as a GMP Complied Site by UAE/MoH
2014. 06 Term Sheet Signed with Ache, No. 1 Pharmaceutical Company in Brazil
2014. 06 Supect, the Result of 24 month of Clinical Phase II Presented at the 19th EHA(European Hematology Association)
2014. 07 General Hospital of Beijing, Presented a Paper of Noltec
2014. 07 Noltec, First Time Published on Global Medical Journal “AP&T”
2014. 08 MOU Signed with College of Medicine KOREA University Research and Institute for Industry Cooperation
2014. 09 ‘YangZhou-Il-Yang’, ‘New EU-GMP Plant’ Dedication Ceremony.
2014. 10 Supect, Awarded the Grand Prize for Pharmaceutical Sector of Korea’s New Drug.
2014. 11 won the IR52 Jang Young-shil Award
2014. 12 won the 20 million USD Top Export Award
2015. 01 Initiation of clinical trial phase 1/2a for quadrivalent inactivated Influenza Vaccine (egg-based)
2015. 02 SUPECT, early completion of multi-national/multi-center clinical trial phase 3
2015. 02 Approved market authorization for IL-YANG Flu Vaccine Vial INJ.(Trivalent inactivated influenza vaccine)
2015. 05 SUPECT, Clinical trial result presented at Autumn conference of the Korean Society of Hematology(KSH)
2015. 06 “SUPECT” validated as a potential treatment for Acute Myeloid Leukemia(AML)
2015. 06 Candidate material for New Drug confirms efficacy on “Ebola Virus”
2015. 07 Discover potential “MERS Virus” treatment substance
2015. 07 License Agreement for ‘NOLTEC’ signed with a Mexican pharmaceutical company, “Chinoin”
2015. 07 Super leukemia treatment SUPECT, applied for 1st line treatment
2015. 07 Memorandum Of Understanding(MOU) signed with Public research laboratory of National Medical Center(NMC)
2015. 08 Entered Term Sheet with BIOPAS of Columbia for SUPECT
2015. 10 Initiated Phase III Clinical trial for Quadrivalent Influenza Vaccine
2015. 10 Super leukemia treatment SUPECT approved for 1st line treatment
2015. 11 Completion ceremony of Chungbuk Jecheon EU-GMP facility
2015. 12 SUPECT, Orally presented its Final Phase III Clinical Trial Results at 2015 American Society of Hematology
(ASH) Annual Meeting
2015. 12 IL-YANG PHARM, awarded “Certificate of Minister of Ministry of Health” under recognition of great
pharmaceutical product development merit
2015. 12 Mr. Il Hwi JUNG(Overseas Department) awarded “10 Most Influential Global Citizen in Jangsu” award from
Jangsu Province of China
2016. 01 IL-YANG PHARM, Opening Ceremony for the Fiscal Year 46
2016. 01 IL-YANG PHARM’s Yongin Plant designated as “Yongin Urban High-Tech Industrial Complex”
2016. 02 SUPECT, Launching Ceremony for 1st Line Therapy
2016. 02 Yongin IlYangHippo Urban High-Tech Industrial Complex MOU
2016. 02 IL-YANG PHARM, MOU signed with Gyeongbuk Institute for Bio Industry
2016. 02 “NOLTEC”, New Anti-Ulcer Agent Drug – Marketing Authorization Approved in Ecuador
2016. 03 SUPECT, Presented Phase III Clinical Trial Results at 2016 Highlight of ASH in Asia-Pacific (2016 HOA)
2016. 04 Head of National Institute of Food and Drug Safety Evaluation visited IL-YANG Eumsung Vaccine plant
2016. 05 IL-YANG, entered MOU with Cha Vaccine R&D Center for cooperate R&D of Flu Vaccines and other
2016. 05 Discovered an effective material for ‘Zika’ and ‘MERS’ virus treatment.
2016. 05 New influenza vaccine research project finally selected as governments’ “Infectious diseases
crisis management technology development“ contest.
2016. 06 ‘H7N9 Vaccine’ Avian Influenza vaccine, presented at 35th American Society for Virology (ASV) Annual Meeting.
2016. 06 SUPECT, signed License and Supply Agreement with Colombian company called BIOPAS.
2016. 07 Development of MERS virus treatment, selected as governmental research project
2016. 08 Development of Parkinson diseases treatment with Johns Hopkins (USA) initiated.
2016. 09 NOLTEC, signed Licensing agreement signed with Russian company called R-PHARM.
2016. 09 Embryonic based Quadrivalent influenza vaccine approval by MFDS.
2016. 09 SUPECT, clinical phase 3 study result orally presented at “18th Annual John Goldman Conference”.
2017. 01 Opening Ceremony for the Fiscal Year 47
2017. 01 SUPECT, IND submitted for clinical phase 3 in China.
2017. 03 Recognized as diligent taxpayer of Yongin local tax
2017. 05 SUPECT, clinical phase 3 study results presented at 58th the Korean Society of Hematology.
2017 .06 NOLTEC, first export to Ecuador.
2017. 06 NOLTEC, first export to Cambodia.
2017. 06 SUPECT, long-term clinical study results presented at 22nd European Society of Hematology.